reducing cardiac late effects in pediatric cancer survivors
This virtual meeting was an opportunity for childhood cancer survivors and caregivers to speak to the Food and Drug Administration (FDA) and other experts about the need to develop new drugs that protect the heart and reduce cardiac late effects caused by harsh chemotherapy and radiation treatments.
chemotherapy-induced hearing loss
The pediatric patient population with chemotherapy-induced hearing loss represents a segment of the cancer survivor community with a severe burden of disease with great unmet medical need. An externally-led, FDA-approved Patient Focused Drug Development (PFDD) meeting was held in 2018 near Washington, DC to explore these issues in-depth.
